tazemetostat
tazemetostat: developed by 1 company · 16 clinical trials tracked · 1 FDA decision.
tazemetostat evidence translation
What we can confirm
1 FDA record · 16 tracked trials
What it means
What to watch
Prepared research question
How could tazemetostat → EPZM affect its developer, and what evidence supports the link?
Traceable citations · Unknowns marked
See linked entities and source evidence8 indications · 1 study sponsors
Development Pipeline (1)
| Company | Phase |
|---|---|
| Epizyme, Inc. (EPZM) | Phase 3 |
Clinical Trials (16)showing 10 most recent
A Phase 2, Open-label, Single-Arm Clinical Trial to Investigate the Efficacy and Safety of Oral Tazemetostat for the Treatment of Adult Participants Age 18 and Over With Relapsed/Refractory Follicular Lymphoma Lacking the EZH2 Gain-of-Function (GOF) Mutation
Primary endpoint: Objective response rate (ORR) assessed by an independent review committee (IRC)
Phase I Study to Evaluate Safety and Tolerability of Tazemetostat in Relapsed/Refractory Peripheral T-cell Lymphoma
Primary endpoint: Identify the recommended phase II dose of Tazemetostat
Randomized Phase II Study of the Addition of Targeted Therapeutic Agents to Tafasitamab-Based Therapy in Non-Transplant-Eligible Patients With Relapsed/Refractory Large B-Cell Lymphoma
Primary endpoint: Progression-free survival (PFS)
TAZNI: A Phase I/II Combination Trial of Tazemetostat With Nivolumab and Ipilimumab for Children With INI1-Negative or SMARCA4-Deficient Tumors
Primary endpoint: Incidence of Grade 3 or Higher Treatment-Related Toxicity
Phase I Trial of Tazemetostat in Combination With Venetoclax in Patients With Relapsed/Refractory Non-Hodgkin Lymphoma
Primary endpoint: Maximum-tolerated dose (MTD) determination (Part 1)
A Single Arm Phase I/II Study of Tazemetostat With Rituximab and Abbreviated Bendamustine in the Frontline Treatment of High Tumor Burden Follicular Lymphoma Big Ten Cancer Research Consortium BTCRC-LYM20-463
Primary endpoint: Phase I: Evaluate safety and tolerability of tazemetostat with bendamustine and rituximab (BR)
Phase 2 Study Using Tazemetostat in Patients With Recurrent/Refractory and/or Metastatic Malignant Peripheral Nerve Sheath Tumors (MPNST)
Primary endpoint: Objective Response Rate
Combining Epigenetic And Immune Therapy to Beat Cancer. CAIRE Study
Primary endpoint: Assessment of antitumor activity of durvalumab combined with tazemetostat for cohort A
A Phase Ia/Ib Study of Talazoparib in Combination With Tazemetostat in Metastatic Castration-resistant Prostate Cancer (mCRPC)
Primary endpoint: Rate of Dose Limiting Toxicity (DLT)
Symphony-1: A Phase 1b/3 Double-Blind, Randomized, Active-Controlled, 3-Stage, Biomarker Adaptive Study Of Tazemetostat Or Placebo In Combination With Lenalidomide Plus Rituximab In Subjects With Relapsed/Refractory Follicular Lymphoma
Primary endpoint: Recommended Phase 3 Dose (RP3D) of tazemetostat in combination with rituximab and lenalidomide (R2)
FDA Decisions1 records
Frequently asked questions
Who is developing tazemetostat?
tazemetostat is being developed by Epizyme, Inc..
How many clinical trials involve tazemetostat?
BioSniper tracks 16 clinical trials involving tazemetostat.
What is tazemetostat's latest FDA decision?
The most recent tracked FDA decision for tazemetostat is Approval for 1 INDICATIONS AND USAGE TAZVERIK is a methyltransferase inhibitor indicated for the treatment of: Adults and pediatric patients aged 16 years and older with metastatic or locally advanced epithelioid sarcoma not eligible for complete resection. ( 1.1 ) Adult patients with relapsed or refractory follicular lymphoma whose tumors are positive for an EZH2 mutation as detected by an FDA-approved test and who have received at least 2 prior systemic therapies. ( 1.2 ) Adult patients with relapsed or re, dated January 23, 2020.